-
Media ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
-
Media ReleaseNovartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
-
Media ReleaseNovartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
-
Media ReleaseNovartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
-
Media ReleaseReal-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
-
Media ReleaseNovartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
-
Media ReleaseNovartis to fund five innovative ideas to support patients and the sickle cell community
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients